Year: 2024

Equinor ASA (OSE: EQNR, NYSE: EQNR) announced on 24 July 2024 an ordinary cash dividend per share of USD 0.35 and an extraordinary cash dividend per share of USD 0.35 for second quarter 2024. The NOK cash dividend per share is based on average USDNOK fixing rate from Norges Bank in the period plus/minus three business days from record date 19 November 2024, in total seven business days. Average Norges Bank fixing rate for this period was 11.0741. Total cash dividend for second quarter 2024 of USD 0.70 per share is consequently NOK 7.7519 per share. On 29 November 2024, the cash dividend will be paid to relevant shareholders on Oslo Børs (Oslo Stock Exchange) and to holders of American Depositary Receipts (“ADRs”) on New York Stock Exchange. This information is published in accordance with the requirements of the Continuing...

Longer-term 96-week results from Scemblix® ASC4FIRST Phase III study in first-line Ph+ CML-CP to be presented following recent FDA approval based on 48-week dataLate-breaking Kisqali®* 4-year analysis on distant disease-free survival in key subgroups with HR+/HER2- early breast cancer from Phase III NATALEE trial also to be presentedPipeline updates demonstrate advancement in research and development programs in hematologic diseases and cancers  Basel, November 25, 2024 – Novartis will present data from more than 65 abstracts, including investigator-initiated trials at the 66th American Society of Hematology (ASH) Annual Meeting & Exposition and the 2024 San Antonio Breast Cancer Symposium® (SABCS). “By prioritizing research in areas of greatest medical need and focusing on earlier stages of disease, we aim to change the...

Press Release Atos receives non-binding offer from the French State to acquire its Advanced Computing activities for an enterprise value of €500 million and up to €625 million including earn-outs Exclusive negotiations with the French State for the potential acquisition of 100% of BDS’s Advanced Computing activitiesProposed enterprise value of €500 million and up to €625 million including earn-outs Previous non-binding offer sent by the French State was on a wider perimeter including Mission Critical System and Cybersecurity Products businesses, in addition to the Advanced Computing business Exclusivity granted until May 31, 2025 Target to sign a Share Purchase Agreement by May 31, 2025 upon reception of customary commercial, employee and administrative authorizations Initial payment of €150 million to be made available upon signing...

Perth, Nov. 25, 2024 (GLOBE NEWSWIRE) — ANNUAL GENERAL MEETING RESULTS Perseus Mining Limited (ASX/TSX: PRU) (Perseus) wishes to release the results of its Annual General Meeting, held on 22 November 2024 at 3pm AWST. All six resolutions were decided on a poll and passed. In accordance with ASX Listing Rule 3.13.2 and Section 251AA of the Corporations Act, details are set out on the next page.ASX/TSX CODE: PRU REGISTERED OFFICE: Level 2437 Roberts RoadSubiaco WA 6008 Telephone: +61 8 6144 1700Email: IR@perseusmining.com ABN: 27 106 808 986 WWW.PERSEUSMINING.COM CONTACTS: Jeff Quartermaine Managing Director & CEOjeff.quartermaine@perseusmining.com Nathan Ryan Media Relations+61 4 20 582 887nathan.ryan@nwrcommunications.com.auThis announcement was approved for release by Jeff Quartermaine, Managing Director and CEO.

Webcast planned for Monday, November 25th at 8:00 AM ET AUSTIN, Texas, Nov. 24, 2024 (GLOBE NEWSWIRE) — Cassava Sciences, Inc. (NASDAQ: SAVA), a clinical-stage biotechnology company focused on developing a novel treatment for Alzheimer’s disease, today announced it will hold a conference call and webcast on Monday, November 25th at 8:00 a.m. Eastern Time.   Event Details:   Date: Monday, November 25thTime: 8:00 a.m. Eastern TimeWebcast: https://lifescievents.com/event/cassava/   A replay of the audio webcast will also be available on the Company Presentations page of the Cassava Sciences website for 90 days following the webcast. About Cassava Sciences, Inc. Cassava Sciences is a clinical-stage biotechnology company based in Austin, Texas. Our mission is to detect and treat neurodegenerative...

Offtake for a minimum of 32,000 tonnes of NOVONIX’s high-performance synthetic graphite material to be supplied to PowerCo from 2027-2031BRISBANE, Australia, Nov. 24, 2024 (GLOBE NEWSWIRE) — NOVONIX Limited (NASDAQ: NVX, ASX: NVX) (“NOVONIX” or the “Company”), a leading battery materials and technology company, and PowerCo SE (“PowerCo”), today announced the signing of a binding offtake agreement for a minimum of 32,000 tonnes of high-performance synthetic graphite material. The material will be supplied to PowerCo over a five-year term starting in 2027. Established by Volkswagen in 2022, PowerCo is committed to ramp-up global battery cell production. PowerCo oversees international factory operations, advances in cell technology, and vertical integration of the battery value chain. PowerCo has identified three gigafactory locations...

Toronto, Nov. 22, 2024 (GLOBE NEWSWIRE) — Faircourt Asset Management Inc., as Manager of the Faircourt Fund (NEO:FGX), is pleased to announce the monthly distribution payable on the Shares of the below listed Fund.Faircourt Funds Trading Symbol Distribution Amount (per share/unit) Ex-Dividend Date Record Date Payable DateFaircourt Gold Income Corp. FGX $0.024 November 29, 2024 November 29, 2024 December 13, 2024Faircourt Asset Management Inc. is the Investment Advisor for Faircourt Gold Income Corp. This press release is not for distribution in the United States or over United States wire services. For further information on the Faircourt Funds, please visit www.faircourtassetmgt.com or please contact 1-800-831-0304. You will usually pay brokerage fees to your dealer if you purchase or sell Shares of the Fund on the NEO...

Delay in filing form 20F has been due to the significant strategic changes pursuant to a previously announced strategic review Notification does not affect the Company’s current listing status Company has been provided until 20 January 2025 to submit a plan to regain compliance VivoPower is targeting filing its 20F before the end of this month and will regain compliance upon such filing LONDON, Nov. 22, 2024 (GLOBE NEWSWIRE) — VivoPower International PLC (Nasdaq: “VVPR”) (the “Company” or “VivoPower”) received a letter (the “Notice”) from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, due to the Company’s delay in filinge its Form 20-F for the period ending June 30, 2024 (the “Filing”), the Company does not presently complywith Nasdaq Listing Rule 5250(c)(1) for continued...

PASCAGOULA, Miss., Nov. 22, 2024 (GLOBE NEWSWIRE) — HII’s (NYSE: HII) Ingalls Shipbuilding authenticated the keel today of Arleigh Burke-class guided missile destroyer Sam Nunn (DDG 133). The ship’s name honors Samuel Augustus Nunn Jr., a former U.S. senator from Georgia and co-founder of the Nuclear Threat Initiative. Nunn was in attendance for the ceremony and was joined by his daughter and ship sponsor, Michelle Nunn. “It is truly an honor to commemorate this moment in the life of the future USS Sam Nunn,” Ingalls Shipbuilding President Kari Wilkinson said. “It continues an important journey for Ingalls shipbuilders in delivering what they do best: hard work, craftsmanship, and quality in support of the Navy and the nation. It is a fitting tribute to the public service of Senator Nunn and his commitment to making a difference...

– Attruby is the first and only approved product with a label specifying near-complete stabilization of TTR. Attruby has been shown to preserve the native function of TTR as a transport protein of thyroxine and vitamin A and to demonstrate benefit on cardiovascular outcomes – Attruby demonstrated the most rapid benefit seen in any Phase 3 study of ATTR-CM to date: – In as few as 3 months, the time to first event (all-cause mortality (ACM) or cardiovascular-related hospitalizations (CVH)) durably separated relative to placebo– A 42% reduction in composite ACM and recurrent CVH events relative to placebo at Month 30– A 50% reduction in the cumulative frequency of CVH events relative to placebo at Month 30 – To honor the courage of our U.S. clinical trial participants, BridgeBio will provide these patients...